Investing.com - Le azioni di Madrigal Pharmaceuticals (NASDAQ: MDGL) sono scese del 4% nelle contrattazioni pre-market di ...

Financial Health Madrigal remains well-funded early on in Rezdiffra's launch. As of March 31, their cash and cash equivalents were $622.517 million. Marketable securities stood at $436.546 million.

In its first full quarter on the market, Madrigal's Rezdiffra had sales of $14.6 million. Despite the strong start, the company's shares dropped 13% ...

Marketing Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon By Ben Adams Nov 5, 2024 10:02am Madrigal Pharmaceuticals MASH GLP-1 Eli Lilly ...

Key Points Madrigal Pharmaceuticals stock plummeted in early-morning trading following its 2023 Q1 earnings report. Bargain hunters were quick to buy the dip, however.